Clinical Trials: Lowereing A1C, Weight Change & CV Data

See results from clinical trials with Trulicity when assessed for A1C reduction, weight change and CV risk reduction.

Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin

Hemoglobin A1c Reduction and CV Risk Improvement: Correlation, Causation and Clinical Recommendations

A Review of the Glycemia Reduction Approaches in Diabetes (GRADE) Study: Comparing the Effectiveness of Type 2 Diabetes Medications

Clinical Trials: Lowereing A1C, Weight Change & CV Data, HCP

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction

Statins may increase diabetes, but benefit still outweighs risk

Tirzepatide for Type 2 Diabetes and Weight Management

Incretins: How we got here, where we're at and what is coming next - DiabetesontheNet

1.5 - Jewelry

Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs - ScienceDirect

PDF] Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.

Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how? A narrative literature review